Abstract
Loss of heterozygosity of the short arm of chromosome 12 is a frequent event in a wide range of haematological malignancies and solid tumours. In previous studies, the shortest commonly deleted region was delimited to a 750-kb interval, defined by the markers D12S89 and D12S358, in pre-B acute lymphoblastic leukaemia patients, suggesting the presence of a tumour suppressor locus. Here we report the construction of a transcriptional map that integrates the data obtained by genomic sequence analysis, EST database search, comparative analysis and exon amplification. We identified seven putative transcriptional units as well as six pseudogenes. Four of these candidate genes were already known: ETV6, encoding an ets-like transcription factor, LRP6, a member of the LDL receptor gene family, BCL-G, a recently identified pro-apoptotic gene and MKP-7, encoding a new member of the dual-specificity phosphatase family. The products encoded by the three new genes identified in this study, LOH1CR12, LOH2CR12 and LOH3CR12, have no clear homology to known proteins. The gene predictions were all confirmed by expression analysis using RT–PCR and Northern blot. This transcriptional map is a crucial step toward the identification of the tumour suppressor gene at 12p12.
Similar content being viewed by others
Introduction
The short arm of chromosome 12 is frequently rearranged in a wide variety of haematological malignancies of both myeloid and lymphoid origins.1,2,3 Most of these 12p alterations result from unbalanced translocations and deletions that lead to a loss of genetic material.4 The frequent loss of genetic material in tumour cells is usually indicative of the inactivation of tumour suppressor genes, which prompted the search for a suppressor locus on chromosome 12p. Loss of heterozygosity studies showed hemizygous deletions of chromosome 12p12 in 26 to 47% of pre-B acute lymphoblastic leukaemia (ALL) cases, making it one of the most common genetic alterations found in this disease.5,6,7 The construction of both high-resolution genetic and physical maps led to the delineation of the shortest commonly deleted region within a 750 kb interval delimited by markers D12S89 and D12S358.8,9,10 The existence of a putative 12p12 tumour suppressor gene is further substantiated by the observation of hemizygous deletions in a variety of haematological malignancies, as well as in certain solid tumours including breast, lung, ovarian and prostate carcinomas.11,12
This region was shown to contain two known genes, LRP6 and ETV6. LRP6 encodes a member of the LDL receptor family13 that was recently shown to act as the WNT co-receptor.14,15,16 However Baens et al.10 failed to reveal any inactivating mutations in leukaemia patients. ETV6, also known as TEL, is a member of the ets-like family of DNA binding proteins, that was originally identified by virtue of its fusion to the platelet-derived growth factor receptor β (PDGFRβ) in chronic myelomonocytic leukaemia with the translocation t(5;12) (q33;p13).17 Recently, it has been shown that ETV6 acts as a transcriptional repressor of several matrix metalloproteinases and that its expression could counteract the transformation of cultured cells by ras.18,19 However, mutational analysis failed to detect deleterious mutations in the second ETV6 allele of ALL patients with hemizygous deletion at this locus6,20 as expected for a classical tumour suppressor gene. These observations taken together led to the suggestion that an as yet unidentified suppressor locus might be located between D12S89 and D12S358.11
Here, we describe the application of a strategy that integrates the use of data mining tools, exon amplification experiments, gene expression studies and comparative genomic analysis to identify putative transcriptional units in the chromosome 12p12 locus. This strategy led to the identification of seven genes, including three uncharacterised genes, and six pseudogenes, indicating the usefulness of integrating different complementary genome-based approaches to identify candidate genes in a large chromosomal interval.
Materials and methods
Genomic clones
BAC clones RP11-525I13, RP11-267J23, RP11-757G14 and RP11-253I19 (GenBank accession numbers AC022222, AC007537, AC007621 and AC007619 respectively) were obtained from Incyte Genomics, Inc (St-Louis, MO, USA). The sequence of these BACs, of BAC RPCI11-180M15 (GenBank accession number AC008115) as well as the whole ETV6 contig (GenBank accession numbers NT_000600, AC005989 and NT_000601) were selected for analysis based on their localization within or near the shortest commonly deleted region according to the chromosome 12 physical map at the Human Genome Sequencing Center, Baylor College of Medicine (http://www.hgsc.bcm.tmc.edu).
Sequence analysis
The genomic sequences available from the selected BAC clones were used as queries for BLAST searches and analysed using the NIX software (http://www.hgmp.mrc.ac.uk/NIX) that displays the results from 15 different prediction algorithms (Grail-CpG, Grail-exons, FGenes, Hexon, FEX, GenScan, etc) and BLAST analysis on many public databases (dbEST, Unigene, htgs, etc.). The programme Exofish (http://www.genoscope.cns.fr/externe/tetraodon) was used to identify the presence of conserved regions at the protein level between the human sequences and the genome of Tetraodon nigroviridis. All other sequence analysis were performed using BLAST or CD-Search programmes on the NCBI site (http://www.ncbi.nlm.nih.gov). Multiple sequence alignments were obtained using the ClustalW algorithm21 and manually edited using the SeaView programme (http://pbil.univ-lyon1.fr/software/seaview.html). Alignments were displayed using the BOXSHADE programme (http://www.ch.embnet.org/software/BOX_form.html).
Exon amplification
Exon amplification was performed using the Exon Trapping System (GibcoBRL-Life Technologies, Burlington, Ontario, Canada) according to the manufacturer's recommendations. Briefly, BAC clones were partially digested with Sau3A. The resulting restriction fragments ranging from 2.5 to 4 kb were isolated from 1% agarose gels and subcloned into BamH1-digested pSPL3. Individual subclones were pooled and transfected into 80%-confluent COS-7 cells. Total cellular RNA was extracted 24 h after transfection and used as a template for RT–PCR using vector-specific primers. The fragments containing putative trapped exons were subcloned into pAMP10 and sequenced using T7 primer.
5′- Rapid amplification of cDNA ends (RACE)
Human testis Marathon-Ready cDNA (Clontech, Palo Alto, CA, USA) was used to amplify the transcript 5′ ends according to the manufacturer's instructions. Briefly, 200 ng of Marathon-ready cDNA was amplified with AP1 primer and a gene-specific primer: 11962RACE (CTGTCCATGACTCATTTGCTGAACA), 11962RACE2 (AGGTGGTTAGTTCTGCCAGGCGAGT), LOH2RACE (CCTTTAAGGTGGCATCGCCCTAAGT) or LOH2RACE2 (CTAATCCGGAACTGAAGGTCTTGCG) by Touchdown PCR. The resulting RT–PCR products were analysed on 1% agarose gel, transferred to nylon membranes (Hybond N+, Amersham-Pharmacia Biotech Baie d'Urfé, Canada) and hybridised with a radioactive internal oligonucleotide to assess the specificity of the bands. The sequence of the putative 5′end-derived exons was determined by dideoxy sequencing using the Thermo Sequenase Radiolabelled Terminator Cycle Sequencing kit (USB, Cleveland, OH, USA) following the subcloning of the PCR products into pGEMT-easy (Promega, Montreal, Canada).
RNA expression analysis by RT–PCR
Normal human brain, testis and prostate RNAs were obtained from Clontech (Palo Alto, CA, USA). Placenta, peripheral blood and bone marrow RNAs were isolated from healthy subjects using standard procedures. Following DNAse-treatment, the RNA samples were incubated at 37°C for 60 min in the presence of 15 μM of random hexamers, 0.2 mM of each dNTPs and 200 U of MMLV reverse transcriptase (Gibco–BRL, Life Technologies, Burlington, Canada). The cDNAs were amplified using 0.2 mM dNTP, 0.4 μM each primer and 2 U of ELONGase polymerase (Gibco–BRL, Life Technologies, Burlington, Canada) in a 60 mM Tris-SO4 pH 9.0 buffer containing 18 mM of (NH4)2SO4, 8% of DMSO and 1.5 mM of MgSO4. The primers amplifying the entire coding regions were 11962F (GTGGGTGTGACCTGGAAGAAAT) and 11962R (TGCACAGGACCACAGTAGACA) for the BCL-GL gene; 97818F (CAAAATTGTTGAGCTGCTGAAAT) and 97818R (GGGGAAGTGCAGAAGTAGGTC) for the BCLGM gene; DUSPF (CTCGAGGGTGGGAAAAGAGGACTTATTG) and DUSPR (GGATCCTTTCAGATTTACAGGGAATTTTT) for the MKP-7 gene; LOH1F (CTCGAGCCGCCGTTCTTCTGCTG) and LOH1R (GGATCCCCTTAGCTCCACACGTCCTC) for the LOH1CR12 gene; LOH2F (GGCTACGCAAGACCTTCAGTT) and LOH2R (ACTGCTTAGTGGGCCCTTCCCAGTC) for the LOH2CR12 gene; FLJF (CTCGAGCCTTGACCTTTGAAGACCAAAA) and FLJR (AAGCTTAGAGACACCGAGTTCCATCC) for the LOH3CR12 gene. The cycling conditions were as follows: initial denaturation of 2 min at 94°C, 35 cycles of 94°C for 30 s, 60–64°C for 30 s, and 72°C for 60 s, and a final extension at 72°C for 10 min. RT–PCR products were revealed by 1 or 2% agarose gel electrophoresis. They were then excised from the gel, cloned into pGEMT-easy (Promega, Montreal, Canada) and sequenced completely.
Northern blot hybridisation
Gel-purified RT–PCR products (see above) were radiolabelled by random priming and used as probes to hybridise multiple Tissue Northern Blots (Human MTN Blot I, Human MTN Blot II and Human Immune System MTN Blot II, Clontech, Palo Alto, CA, USA). The hybridisations were carried out at 50°C in a solution containing 50% formamide, 10% dextran sulfate, 1% SDS, 1 M NaCl, 50 μg/ml fish sperm DNA and 5×106 c.p.m./ml of a given probe. Following hybridisation, the filters were washed at high stringency with 0.1×SSC, 0.1% SDS at 55°C and autoradiographed at −80°C with X-OMAT Kodak films.
Results
Sequence analysis
The availability of BAC sequences within the chromosome 12p12 suppressor locus, as part of the human genome sequencing project, provided the molecular framework to search for transcribed sequences. Four BAC clones, RP11-525I13, RPCI11-267J23, RP11-757G14 and RP11-253I19, mapped between markers D12S89 and D12S358. Only partial and unordered sequences were available for clones 525I13 and 253I19 at the time of the writing of this paper. The genomic gap between the marker D12S89 and the BAC 525I13 (Figure 1) was filled by using the data from the complete sequence of the ETV6 locus.22 This genomic sequence was analysed with the NIX programme to identify putative transcribed sequences. We identified six pseudogenes based on the absence of introns and the presence of stop codons within the consensus coding sequence. In addition, we found four CpG islands and over 90 EST clusters, 38 of them corresponding to Unigene entries. Many of these ESTs appear to be artefacts as suggested by their low representation (i.e. either unique or only two members) or by the presence of a polyA tail at their 3′ end in the corresponding genomic sequence without any upstream polyadenylation signal. This could have allowed oligo dT priming during RT–PCR on mRNA, but also on genomic DNA or on unspliced RNA. To restrict the number of ESTs to analyse, they were classified according to the following characteristics: (1) presence of spliced sequence, (2) homology with genes/ESTs or proteins, when translated, from other species, (3) evolutionarily conserved as shown by Exofish analysis, (4) matches with trapped exon(s) and (5) presence of a polyadenylation signal at the 3′ end of the cluster. In this study, only the EST clusters that fulfil at least one of the above characteristics were further investigated.
The EXOFISH algorithm compares genomic sequences to 150 Mb of T.nigroviridis sequence (corresponding to 33% of its genome) at the protein level. This algorithm has been successful in detecting two thirds of the known genes on human chromosome 22 with an estimated specificity of over 90%.23 In this study, 33 hits (termed ecores) corresponded to four EST clusters (Table 1) and five pseudogenes (data not shown), but to no other regions. The exon trapping technique identified seven exons corresponding to three of the clusters found in the region analysed (Table 1). Six other trapped sequences did not reveal any match in the EST database, but the absence of a translation frame may suggest false positives rather than actual exons. Applying all these criteria, only 20 clusters were kept for further analysis (Table 1). None of the other clusters analysed contained an ORF that could encode a protein. Of the 20 clusters selected, eight contained spliced sequences and were considered the most interesting. Except for two clusters, BCL-GM and LOH2CR12, they all had clear orthologues from other species in the dbEST. Unigene cluster Hs.97818 corresponded clearly to an alternative splicing form of the BCL-G gene (see below). The physical relationship of these predicted genes within the commonly deleted region is presented in Figure 1. To be more informative, we have extended the map on the proximal side in order to include the known genes CREBL2, GPR19 and CDKN1B. No other putative transcriptional units were present on the corresponding BAC clone RPCI11–180M15 (data not shown). Two of the clusters corresponded to the ETV622 and LRP613 genes that were previously characterised in detail and mapped to this region13,22 and as such will not be further discussed in this section.
By using the assembled ESTs and exon prediction programmes it was possible to obtain an open reading frame (ORF) starting with a methionine for all the remaining selected clusters except for LOH2CR12 (Figure 2). The region encompassing the putative ORFs of all the clusters could be amplified by RT–PCR in multiple tissues, confirming the gene prediction (Table 2). Furthermore, many alternative splicing species could be observed by this analysis (see below).
Characterisation of the candidate genes
The human BCL-G gene was originally characterised as composed of six exons that encode at least two known splicing variants, BCL-GL (long form, 327 amino acids) and BCL-GS (short form, 252 amino acids) isoforms.24 The BH3 domain, one of four BCL-2 homology domains (BH domain), is found in both isoforms and confers pro-apoptotic activity. The longer variant also possesses a BH2 domain, which negatively regulates this activity.24 RT–PCR (Table 2) and Northern blot (data not shown) analyses revealed that while BCL-GS is only expressed in the testes, BCL-GL is expressed in many tissues including bone marrow, prostate, pancreas, colon, but predominantly in the testes, which is in agreement with Guo et al.24 Our Blast analyses and 5′RACE experiments suggest the presence of seven additional exons (Figure 2). The first three 5′ upstream exons (exons 1A to 1C) are non-coding and various combinations of these exons were observed in the dbEST. Alternative splicing involving the four additional 3′ exons (exons 7 to 10) could generate a new isoform, termed BCL-GM for median, whose 276 amino acid product would also lack box BH2. By RT–PCR, BCL-GM was shown to be expressed only in the testes (Table 2).
MKP-7 has 7 exons (Figure 2) and codes for a new member of the dual-specificity phosphatase family that dephosphorylates MAP kinases.25 This gene shows 55% sequence identity with DUSP8/hvh-5, a closely related dual-specificity phosphatase.25 Northern blot hybridisation with a MKP-7 probe revealed the expression of two mRNA species of 4.0 and 6.0 kb in all tissues tested (Figure 3). The detection of weakly hybridising 3.0 and 5.5 kb bands in some tissues, especially in the brain, could be due to cross-hybridisation with the related DUSP8/hvh-5 species, which correspond to the observed size and distribution of this mRNA.26 By RT–PCR, we also observed a splicing variant, in which exon 4 is skipped and that is present in every tissue analysed by RT–PCR, although expressed at lower levels (Table 2). The predicted protein would be truncated and lack its phosphatase domain, keeping only the conserved cdc25 domain putatively involved in protein–protein interactions.27
LOH1CR12 has four exons (Figure 2) that encode a predicted 195 amino acid protein that shows high homology with hypothetical proteins from distant species: mouse BAB25030 (95% identity), D.melanogaster CG11802 (35% identity and 59% similarity) and C.elegans F59E12.11 (27% identity and 55% similarity) (Figure 4). The function of these proteins is not known, but they have some homology to one of the spectrins repeats of the TRIO protein and to an uncharacterised region from Mekk4 protein (Figure 4). Three major mRNA species at 1.2, 1.4 and 4.5 kb were detected in all tissues tested by Northern blot (Figure 3). Bands at 1.7 and 6 kb were also detected at lower levels. RT–PCR and sequencing experiments revealed the presence of a splicing variant skipping exon 2, thus explaining the 1.2 and 1.4 kb species. Interestingly this variant was not observed in the SJNB-7 cell line (Table 2). Both bands at 4.5 and 6 kb could be explained by the alternative use of termination sites (see below).
The LOH3CR12 gene is constituted of five exons (Figure 2). The function of this gene product is unknown, but it possesses low homology to the syndecan domain, which is characteristic of membrane heparan sulfate proteoglycans (Figure 5). Blast analysis also indicated low homology to hepatocyte growth factor activator inhibitor protein and to glycoprotein 1a (data not shown). Homologues from various species were observed, including the mouse RIKEN cDNA 9130403P13 with 62% identity and 66% similarity at the protein level (Figure 5). We have also found a transcript variant (GenBank accession number AK023622) that is characterised by the presence of the 102 bp coding intron 2 that is translated in phase when left unspliced (hatched box in Figure 2). Both transcripts were present in every tissue tested by RT–PCR, the longest being the most abundant (data not shown).
The definitive structure of the LOH2CR12 gene is still unknown at this moment: only two exons were identified from the human EST database. All those ESTs, as well as the most upstream sequence obtained by 5′RACE analysis, stopped in a GC-rich region corresponding to the LOH1CR12 CpG island (Figure 6). By Blast analysis, a 500-bp mouse genomic fragment (clone Ti no.10921056) revealed clear homology to 5′ exons from both LOH1CR12 and LOH2CR12. A common ORF could be constructed for LOH2CR12, although the start codon was not observed and is thus presumably located in another unidentified exon (Figure 6). No homology was found with proteins from other species. RT–PCR and sequencing experiments confirmed the gene prediction and very low levels of expression were observed in the bone marrow, prostate and testes. It also revealed that its 3′ end corresponded to Unigene cluster Hs.67553 (Table 1). The weak expression could explain the absence of signal in the Northern blot analysis (data not shown).
Alternative termination
In previous studies, ETV6 was shown to use alternative termination sites.22 Three of the EST clusters found in our study, Hs.169081, Hs.293972, Hs.146381, clearly correspond to the 3′ ends of the ETV6 transcripts of 2.4, 4.3 and 6.2 kb, respectively, when placed in the genomic context (Table 1). LRP6 possesses two transcripts of 6 and 11 kb.13 Using the same reasoning, it is clear that the 3′ end of clusters Hs.23672, which includes the coding sequence of LRP6, and Hs.41269, containing over 90 ESTs, correspond to the 3′ end of the short and long transcripts, respectively. All the other identified transcribed sequences, with the exception of LOH2CR12, were characterised by at least two different mRNA species by Northern hybridisation (Figure 3) suggesting the presence of alternative splicing or alternative usage of termination sites. The latter is supported by the identification of large Unigene clusters with consensus 3′ polyadenylation sites (but without coding potential), that could explain the 6 kb-LOH3CR12, 6 kb-MKP-7 and 4.5- and 6 kb- LOH1CR12 mRNAs respectively (see Table 1 and Figures 2 and 3). RT–PCR and sequencing experiments confirmed the existence of the longer transcripts for each gene (data not shown).
CpG islands
The presence of a CpG island usually indicates the 5′ extremity of an housekeeping gene. The analysis of the genomic sequences with Grail/CpG predicted 4 CpG islands in the D12S89-D12S358 interval. Three of them seem to be associated with the 5′ ends of LRP6, LOH3CR12 and LOH1CR12. ETV6 also possesses a 5′ CpG island,22 which is located outside the interval analysed (Figure 1). As predicted, all of them are expressed in every tissue analysed in contrast with BCL-G and LOH2CR12 whose expression is more restricted (Table 2). The 5′ end of MKP-7 could not be identified since it lies in a gap between the BACs 253I19 and 180M15 (Figure 1), but Baens et al.10 placed a CpG island in that region. The other CpG island is associated with the pseudo-prothymosin gene and probably does not reflect the presence of a transcribed gene. Indeed, it has been shown that this CpG island is methylated in vivo.10
Discussion
Here we report the construction of a detailed transcriptional map of the putative chromosome 12p12 tumour suppressor locus using a combination of different approaches (comparative analysis, exon trapping and gene prediction algorithms). We identified seven distinct candidate transcriptional units, including ETV6, LRP6, BCL-G and MKP-7 that were characterised previously.13,22,24,25 LOH1CR1, LOH2CR12 and LOH3CR12 are three novel genes characterized in this study.
ETV6 is a nuclear phosphoprotein that is widely expressed in all normal tissues28 and plays an important role in angiogenesis29 as well as in the normal development of the haematopoietic system.30 Unlike most Ets-like proteins, ETV6 acts as a transcriptional repressor recruiting proteins involved in the histone-deacetylase pathway.31,32 It can also block the transformation process induced by the overexpression of ras in cultured cells.19 LRP6 is a member of the LDL-receptor family that has been recently shown to be an essential component of the Wnt pathway.14,15,16 This pathway is involved in many different cancers and developmental defects in humans.33 BCL-G is a new member of the BCL-2 family that possesses proapoptotic activity.24 BCL-G has multiple splicing variants generating three proteins of different lengths. BCL-GL contains both conserved boxes BH3 and BH2, whereas BCL-GS lacks box BH2. The latter is a more potent apoptosis inducer than the longer variant indicating that Box BH2 has an inhibitory role.24 We found a third variant, BCL-GM, that also lacks box BH2 thus predicting a function similar to BCL-GS. Considering their function, ETV6, LRP6 and BCL-G are good candidate genes, but the failure to detect any inactivating mutations in these genes in leukaemia patients does not support a role as classical tumour suppressor genes.10,20,24
MKP-7 is a new member of the dual-specificity ser/thr and tyr phosphatases. Phosphatases play important roles in the regulation of intracellular signalling and have been associated with either oncogenic or tumour suppressor activity.34 For instance, PTEN, another dual-specificity phosphatase, is often inactivated in human cancers, particularly endometrial carcinomas and glioblastomas, and germline mutations have been reported in patients affected with either of these two tumour predisposing syndromes.35 MKP-7 was recently shown to bind and inactivate p38 MAPK and JNK/SAPK involved in the transmission of cellular growth signals to the nucleus.25
LOH1CR12 and LOH3CR12 have no strong sequence similarity with proteins of known function, but some speculations can be made. LOH1CR12 has homologues at least in mouse, C.elegans and D.melanogaster and Blast analysis revealed some sequence similarities at the protein level with a region encompassing one of the spectrin repeats of TRIO and other closely related proteins. TRIO is a guanine nucleotide exchange factor that regulates the actin cytoskeleton organization, cell motility and cell growth via activation of Rho GTPases.36,37 Spectrin repeats are usually found in proteins associated with the cytoskeleton. Although the specific function of LOH1CR12 cannot be inferred, the fact that it is conserved throughout evolution points to an important role for this protein. Homologues of protein LOH3CR12 are present in various mammals including the mouse, but no homologues have been identified in lower vertebrates. It possesses a syndecan domain and has also low homology with glycoprotein 1a and hepatocyte growth factor activator inhibitor. All of them are membrane-bound or transmembrane proteins. Syndecans are transmembrane heparan sulphate proteoglycans that play an important role in cell-matrix and cell–cell interactions.38 Finally, the structure of LOH2CR12 is still incomplete and the characterisation of the remaining 5′ exons will be necessary to infer a putative function for its encoded protein.
Previous expression analysis has demonstrated that ETV6 and LRP6 are present in a wide range of tissues.13,28 In this study, we showed that LOH1CR12, LOH3CR12 and MKP-7 also have a broad range of expression. Only BCL-G and LOH2CR12 have a more restricted pattern of expression. BCL-G variants, BCL-GS and BCL-GM are only expressed in the testes while BCL-GL is expressed predominantly in the testes and also at lower levels in other tissues including prostate, pancreas and the bone marrow, which is consistent with the work done by Guo et al.24 The expression of LOH2CR12 was observed only by RT–PCR analysis in certain tissues including testes, prostate and bone marrow. The fact that all the genes in the commonly deleted region from ALL patients are expressed in the bone marrow makes them interesting tumour suppressor gene candidates.
The observation that more EST clusters were identified than the number of genes in the region was puzzling at first. One explanation is the fact that most of the genes identified in our study seem to use alternative termination sites, giving rise in the database of multiple independent clusters, since most of the ESTs are primed at their 3′ end. Whether the latter phenomenon is specific to the genomic context of this locus is not known, but many examples of alternative termination exist in the literature.39 The exact role of the alternative 3′UTRs length is unclear since it does not affect the coding sequence, but it could be associated with the relative mRNA stability. For instance, the gene eIF-2a uses at least two polyA sites generating two common transcripts of 1.6 and 4.2 kb.40 The smaller transcript is more readily translated in vitro while the longer transcript is more stable. The relative ratios of these transcripts vary with each tissue. The majority of the other clusters, if not all, correspond to artefacts that could be explained by internal or genomic polyT priming during the reverse transcription reaction. Only two small clusters in our analysis, represented by only one or two ESTs, could not be ruled out as artefacts using our criteria, indicating that we probably identified all the genes in the locus.
The construction of a transcription map of this locus and the identification of seven candidate genes provide the molecular framework to identify the tumour suppressor gene(s) at 12p12, a locus frequently deleted in haematological malignancies as well as in many different solid neoplasias.
Accession numbers
Sequence data from this article have been deposited in the EMBL/GenBank Libraries under accession numbers AY040274, AY037865, AY037866, AY037867 and AY038927.
References
Berger R, Bernheim A, Le Coniat M et al. Abnormalities of the short arm of chromosome 12 in acute nonlymphocytic leukemia and dysmyelopoietic syndrome Cancer Genet Cytogenet 1986 19: 281–289
Raimondi SC, Williams DL, Callihan T, Peiper S, Rivera GK, Murphy SB . Nonrandom involvement of the 12p12 breakpoint in chromosome abnormalities of childhood acute lymphoblastic leukemia Blood 1986 68: 69–75
Chan LC, Kwong YL, Liu HW, Lee CP, Lie KW, Chan AY . Deletion 12p in de novo acute myeloid leukemia. An association with early progenitor cell Cancer Genet Cytogenet 1992 62: 47–49
Raimondi SC . Current status of cytogenetic research in childhood acute lymphoblastic leukemia Blood 1993 81: 2237–2251
Stegmaier K, Pendse S, Barker GF et al. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood Blood 1995 86: 38–44
Takeuchi S, Bartram CR, Miller CW et al. Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1 Blood 1996 87: 3368–3374
Baccichet A, Qualman SK, Sinnett D . Allelic loss in childhood acute lymphoblastic leukemia Leuk Res 1997 21: 817–823
Baccichet A, Sinnett D . Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia Br J Haematol 1997 99: 107–114
Aissani B, Sinnett D . Fine physical and transcript mapping of a 1.8 Mb region spanning the locus for childhood acute lymphoblastic leukemia on chromosome 12p123 Gene 1999 240: 297–305
Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P . A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p) Genomics 1999 56: 40–50
Aissani B, Bonan C, Baccichet A, Sinnett D . Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3? Leuk Lymphoma 1999 34: 231–239
Kibel AS, Freije D, Isaacs WB, Bova GS . Deletion mapping at 12p12-13 in metastatic prostate cancer Genes Chromosomes Cancer 1999 25: 270–276
Brown SD, Twells RC, Hey PJ et al. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family Biochem Biophys Res Commun 1998 248: 879–888
Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC . An LDL-receptor-related protein mediates Wnt signalling in mice Nature 2000 407: 535–538
Tamai K, Semenov M, Kato Y et al. LDL-receptor-related proteins in Wnt signal transduction Nature 2000 407: 530–535
Wehrli M, Dougan ST, Caldwell K et al. Arrow encodes an LDL-receptor-related protein essential for Wingless signalling Nature 2000 407: 527–530
Golub TR, Barker GF, Lovett M, Gilliland DG . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation Cell 1994 77: 307–316
Van Rompaey L, Dou W, Buijs A, Grosveld G . Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components Neoplasia 1999 1: 526–536
Fenrick R, Wang L, Nip J et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1 Mol Cell Biol 2000 20: 5828–5839
Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP . Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia Cancer Res 1996 56: 1413–1417
Thompson JD, Higgins DG, Gibson TJ . CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice Nucleic Acids Res 1994 22: 4673–4680
Baens M, Peeters P, Guo C, Aerssens J, Marynen P . Genomic organization of TEL: the human ETS-variant gene 6 Genome Res 1996 6: 404–413
Roest Crollius H, Jaillon O, Bernot A et al. Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence Nat Genet 2000 25: 235–238
Guo B, Godzik A, Reed JC . Bcl-G, a novel pro-apoptotic member of the Bcl-2 family J Biol Chem 2001 276: 2780–2785
Tanoue T, Yamamoto T, Maeda R, Nishida E . A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs J Biol Chem 2001 276: 26629–26639
Martell KJ, Seasholtz AF, Kwak SP, Clemens KK, Dixon JE . hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase J Neurochem 1995 65: 1823–1833
Denu JM, Dixon JE . Protein tyrosine phosphatases: mechanisms of catalysis and regulation Curr Opin Chem Biol 1998 2: 633–641
Poirel H, Oury C, Carron C et al. The TEL gene products: nuclear phosphoproteins with DNA binding properties Oncogene 1997 14: 349–357
Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH . Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL EMBO J 1997 16: 4374–4383
Wang LC, Swat W, Fujiwara Y et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow Genes Dev 1998 12: 2392–2402
Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J . TEL is a sequence-specific transcriptional repressor J Biol Chem 1999 274: 30132–30138
Chakrabarti SR, Nucifora G . The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A Biochem Biophys Res Commun 1999 264: 871–877
Polakis P . Wnt signaling and cancer Genes Dev 2000 14: 1837–1851
Dahia PL . PTEN, a unique tumor suppressor gene Endocr Relat Cancer 2000 7: 115–129
Bonneau D, Longy M . Mutations of the human PTEN gene Hum Mutat 2000 16: 109–122
Debant A, Serra-Pages C, Seipel K et al. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac- specific and rho-specific guanine nucleotide exchange factor domains Proc Natl Acad Sci USA 1996 93: 5466–5471
Seipel K, Medley QG, Kedersha NL et al. Trio amino-terminal guanine nucleotide exchange factor domain expression promotes actin cytoskeleton reorganization, cell migration and anchorage-independent cell growth J Cell Sci 1999 112: 1825–1834
Rapraeger AC . Molecular interactions of syndecans during development Semin Cell Dev Biol 2001 12: 107–116
Edwalds-Gilbert G, Veraldi KL, Milcarek C . Alternative poly(A) site selection in complex transcription units: means to an end? Nucleic Acids Res 1997 25: 2547–2561
Miyamoto S, Chiorini JA, Urcelay E, Safer B . Regulation of gene expression for translation initiation factor eIF-2 alpha: importance of the 3′ untranslated region Biochem J 1996 315: 791–798
Acknowledgements
We thank Zeina Saikali for critical reading of this manuscript. This work was supported by the Canadian Institutes of Health Research (CIHR). Daniel Sinnett is a scholar of the Fonds de la Recherche en Santé du Québec (FRSQ). Alexandre Montpetit and Gino Boily have received studentships from the CIHR and from the FRSQ, respectively.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Montpetit, A., Boily, G. & Sinnett, D. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur J Hum Genet 10, 62–71 (2002). https://doi.org/10.1038/sj.ejhg.5200766
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5200766
Keywords
This article is cited by
-
BCL-G: 20 years of research on a non-typical protein from the BCL-2 family
Cell Death & Differentiation (2023)
-
Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN-γ and TNF-α in intestinal epithelial cells
Cell Death & Disease (2020)
-
Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer
Cell Death & Differentiation (2020)
-
Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression
Oncogene (2019)
-
Molecular processes involved in B cell acute lymphoblastic leukaemia
Cellular and Molecular Life Sciences (2018)